Terms: = Endocrine gland cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Treatment
107 results:
1. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract] [Full Text] [Related]
2. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
3. TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort.
Cruz-Romero SD; González S; Juez JY; Becerra DS; Baldión AM; Hakim JA; González-Devia D; Perdomo S; Rodríguez-Urrego PA
Adv Ther; 2024 Feb; 41(2):792-805. PubMed ID: 38170436
[TBL] [Abstract] [Full Text] [Related]
4. Fine-needle biopsy of thyroid nodules and the contribution of molecular analysis of BRAF and RAS mutations.
Kasko M; Grigerova M; Alemayehu A; Zavodna K; Kasko V; Podoba J
Bratisl Lek Listy; 2023; 124(12):869-872. PubMed ID: 37983279
[TBL] [Abstract] [Full Text] [Related]
5. Macrofollicular Architecture in Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Pitfall in Thyroid Practice.
Yadav S; Kandasamy D; Damle N; Goel R; Chumber S; Sharma MC; Boruah M; Agarwal S
Head Neck Pathol; 2023 Dec; 17(4):899-909. PubMed ID: 37775618
[TBL] [Abstract] [Full Text] [Related]
6.
Alamri AM; Alkhilaiwi FA; Khan NU; Tasleem M
Anticancer Agents Med Chem; 2023; 23(19):2111-2126. PubMed ID: 37287303
[TBL] [Abstract] [Full Text] [Related]
7. Identification of crucial genes involved in thyroid cancer development.
Kalarani IB; Sivamani G; Veerabathiran R
J Egypt Natl Canc Inst; 2023 May; 35(1):15. PubMed ID: 37211566
[TBL] [Abstract] [Full Text] [Related]
8. Case report: Complete response of an anaplastic thyroid carcinoma patient with
Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
[TBL] [Abstract] [Full Text] [Related]
9. Papillary thyroid carcinoma with desmoid-type fibromatosis: the clinicopathological features with characteristic imaging and molecular correlation requiring comprehensive treatment.
Huang H; Li L; Liu X; Zhao L; Cui Z; Zhang R; Chen S
Hum Pathol; 2023 Jun; 136():84-95. PubMed ID: 37019411
[TBL] [Abstract] [Full Text] [Related]
10. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
da Silva TN; Rodrigues R; Saramago A; Pires C; Rito M; Horta M; Martins C; Leite V; Cavaco BM
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651156
[TBL] [Abstract] [Full Text] [Related]
11. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
[TBL] [Abstract] [Full Text] [Related]
12. Genetics of testicular cancer: a review.
Martin FC; Conduit C; Loveland KL; Thomas B; Lewin J; Tran B
Curr Opin Urol; 2022 Sep; 32(5):481-487. PubMed ID: 35855571
[TBL] [Abstract] [Full Text] [Related]
13. Expression and purification of recombinant human CCL5 and its biological characterization.
Ma Z; Zhang J; Wang L; Liu Y; Wang Y; Liu W; Xing G; Cheng K; Zheng W; Xiang L
Protein J; 2022 Apr; 41(2):337-344. PubMed ID: 35524873
[TBL] [Abstract] [Full Text] [Related]
14. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract] [Full Text] [Related]
15. Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological cancer Harboring RAS Mutation: A Case Series.
Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
[TBL] [Abstract] [Full Text] [Related]
16. Clinical Application of Next-Generation Sequencing in Advanced Thyroid cancers.
Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
[No Abstract] [Full Text] [Related]
17. Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid cancers.
Franco AT; Ricarte-Filho JC; Isaza A; Jones Z; Jain N; Mostoufi-Moab S; Surrey L; Laetsch TW; Li MM; DeHart JC; Reichenberger E; Taylor D; Kazahaya K; Adzick NS; Bauer AJ
J Clin Oncol; 2022 Apr; 40(10):1081-1090. PubMed ID: 35015563
[TBL] [Abstract] [Full Text] [Related]
18. Highlights on the Role of
Hafezi S; Saber-Ayad M; Abdel-Rahman WM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638560
[TBL] [Abstract] [Full Text] [Related]
19. New therapeutic opportunities for women with low-grade serous ovarian cancer.
Moujaber T; Balleine RL; Gao B; Madsen I; Harnett PR; DeFazio A
Endocr Relat Cancer; 2021 Nov; 29(1):R1-R16. PubMed ID: 34636747
[TBL] [Abstract] [Full Text] [Related]
20. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
[TBL] [Abstract] [Full Text] [Related]
[Next]